SCLXScilex Holding Co

Nasdaq scilexholding.com


$ 1.80 $ -0.13 (-6.74 %)    

Wednesday, 03-Jul-2024 12:59:53 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 1.8
$ 2.19
$ 0.00 x 0
$ 1.81 x 735
$ 1.78 - $ 2.23
$ 0.73 - $ 6.55
7,851,909
na
184.33M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-11-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-18-2021 06-30-2021 10-Q
13 07-23-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 non-opioid-pain-therapy-focused-semnur-pharmaceuticals-strikes-2b-spac-deal-for-nasdaq-debut

Semnur Pharmaceuticals, a subsidiary of Scilex, plans a business combination with Denali Capital Acquisition Corp. Semnur's...

Core News & Articles

Scilex is expected to be the majority holder of the combined company following completion of the proposed business combination.

 top-performing-industry-etfs-in-june-software-leads-returns-chipmakers-attract-most-inflows

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...

 scilex-approved-a-resolution-to-authorize-management-to-explore-ways-in-which-to-maximize-value-of-semnur-pharmaceuticals-and-sp-102-including-by-way-of-conducting-a-spin-off-merger-dividend-reclassification-or-other-similar-transaction

- SEC Filing  

 hc-wainwright--co-reiterates-buy-on-scilex-holding-maintains-7-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Scilex Holding (NASDAQ:SCLX) with a Buy and maintains $7 price...

 scilex-holding-announces-publication-of-trial-results-for-sp-102-semdexa-in-pain-journal-focuses-on-non-opioid-pain-management-products-for-acute-and-chronic-pain

The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and resea...

 rodman--renshaw-initiates-coverage-on-scilex-holding-with-buy-rating-announces-price-target-of-13

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Scilex Holding (NASDAQ:SCLX) with a Buy rating and announc...

 scilex-holding-presents-poster-on-elyxyb-at-the-annual-scientific-meeting-of-the-ahs-to-be-held-on-june-13-16-2024

Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants...

 reported-earlier-scilex-secures-5-year-term-of-100m-in-royalty-based-financing-for-non-opioid-pain-management-expansion

The Company intends to use the funds to repay the outstanding amount of its existing senior secured loan provided by Oramed Pha...

 scilex-holding-announces-that-many-national-pharmacy-chains-and-independent-pharmacies-have-begun-stocking-gloperba-the-first-oral-liquid-medicine-for-prophylaxis-of-gout-flares

Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.Scilex has officially shipped its recently approved, G...

 hc-wainwright--co-reiterates-buy-on-scilex-holding-maintains-7-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Scilex Holding (NASDAQ:SCLX) with a Buy and maintains $7 price...

 scilex-announces-nationwide-stocking-and-launch-of-gloperba-fda-approved-treatment-for-gout-flares-in-adults

Stocking of GLOPERBA is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and S...

 scilex-holding-company-announces-fda-approval-for-commercial-manufacturing-of-gloperba-a-prophylactic-treatment-for-gout-flares-in-adults-to-launch-june-10-2024

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painf...

 hc-wainwright--co-maintains-buy-on-scilex-holding-lowers-price-target-to-7

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Scilex Holding (NASDAQ:SCLX) with a Buy and lowers the price ta...